ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO1013

Dietary Advanced Glycation End Products Restriction Effects on Intestinal Bacterial Flora and Microinflammation State in Maintenance Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Wang, Meng, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China
  • Liu, Hua, First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China
Background

It had been found that dietary AGEs was related to markers of inflammation and oxidative stress in a population of end stage renal disease (ESRD) patients undergoing dialysis . This study was to explore the effects of dietary advanced glycation end products(AGEs) restriction on microinflammation state and intestinal bacterial flora in maintenance hemodialysis(MHD) patients.

Methods

Patients were randomized to normal group(n=10) continuing the same diet, and intervention group taking a dietary AGE restriction for one month(n=10). Blood and stool samples were collected before and after intervention. Highsensitive C-reactive protein and interleukin-6 were detected. The alteration of gut microbiomes were analyzed by bacterial 16S rDNA amplification and DNA pyrosequencing to determine the presence of bacteria.

Results

Plasma High-sensitive C-reactive protein and interleukin-6 levels were significantly reduced in dietary AGEs restriction group(p<0.05). The number of Bifidobacterium and Lactobaeillus decreased whereas the number of E. coli and Enterococcus faecalis increased p<0.05) in intervention group.

Conclusion

This study showed significant microbiota differences between two groups in MHD patients, might provide evidence for reducing uremic toxin from the view of gut microbiota, and play a role in improving life quality of patient. More research is needed.